All News
Specific ACPAs and Autoantibodies Lead to RA-Associated ILD
A BRASS registry study shows that specific isotypes of anti-citrullinated protein antibodies (ACPAs) can be associated with incident rheumatoid arthritis-associated ILD (RA-ILD).
Read Article
Poorer health outcomes for at-risk patients with fractures
People at high risk of fracture who also have complex or multiple chronic medical conditions are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes, according to a new study from the Garvan Institute of Medical Research.
Read Article
Elevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation
A Longitudinal Swedish study has shown that elevated serum uric acid (SUA) levels has cardiovascular implications and may predict the development of atrial fibrillation (AFib).
Read Article
Best of 2022: Approach to ILD in Myositis Syndromes
Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.
Read Article
JAK Inhibitor Potential in Systemic Sclerosis-Associated ILD
The occurrence of interstitial lung disease (ILD) in Systemic sclerosis portends serious morbid and mortal outcomes for those affected. This review examines the available clinical literature on the potential benefits and outcomes of JAK inhibitor use in SSc=ILD.
Read Article
RECITAL Trial: RTX vs. CTX in CTD-ILD
A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX.
Read Article
RA-ILD takes centre stage
Interstitial lung disease is common in RA, occurring in approximately 8% of RA patients. It is associated with a poor prognosis, and a median survival of 3 years. This important condition has often been neglected within the spectrum of RA research. That is changing, with excellent research initiatives presented at ACR22. I am going to highlight two select abstracts from Monday’s dedicated RA-ILD session.
Read Article
RA-ILD: an update
Interstitial lung disease (ILD) remains a leading cause of mortality in rheumatoid arthritis (RA). Estimates of involvement of ILD in RA remain relatively imprecise (estimated prevalence 5-20%), though this partly reflects the wide spectrum of ILD and differing ascertainment.
Read Article
ACR Best Abstracts - Day 1
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
Read Article
Links:
Links:
Links:
Catherine Sims, MD DrCassySims ( View Tweet)
